Neo Ivy Capital Management Mirati Therapeutics, Inc. Transaction History

Neo Ivy Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 29, 2023	BUY	$27.8 - $45.35 $687,216 - $1.12 Million	24,720 New	24,720 $1.08 Million
Q4 2022 Mar 24, 2023	BUY	$41.27 - $98.62 $77,009 - $184,024	1,866 New	1,866 $84,000
Q2 2022 Aug 16, 2022	SELL	$39.16 - $88.71 $141,445 - $320,420	-3,612 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $273,861 - $545,303	3,612 New	3,612 $296,000
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $91,072 - $135,031	-562 Closed	0 $0

Q3 2020 Nov 17, 2020	SELL	$113.26 - $167.27 $905,173 - $1.34 Million	-7,992 Reduced 93.43%	562 $93,000
Q2 2020 Aug 17, 2020	BUY	$72.01 - $120.39 $615,973 - $1.03 Million	8,554 New	8,554 $976,000
Q3 2019 Nov 21, 2019	SELL	$77.91 - $109.6 $666,442 - $937,518	-8,554 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$59.49 - $104.71 $508,877 - $895,689	8,554 New	8,554 $881,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.